SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
|(State or Other Jurisdiction
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant’s Telephone Number, Including Area Code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 31, 2023, Eric T. Schmidt, Ph.D., resigned from the Board of Directors (the “Board”) of Revolution Medicines, Inc. (the “Company”), effective September 5, 2023. Dr. Schmidt’s resignation was in connection with his acceptance of a position as an investment analyst and not a result of any disagreement with the Company or any matter relating to the Company’s operations, policies or practices.
In connection with the resignation of Dr. Schmidt from the Board and the Audit Committee of the Board (the “Audit Committee”), the Board appointed Lorence Kim, M.D., who currently serves as a member of the Audit Committee, to serve as the Chair of the Audit Committee. Additionally, the Board appointed Alexis Borisy to serve as a member of the Audit Committee to fill a vacancy on the Audit Committee following Dr. Schmidt’s resignation.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|REVOLUTION MEDICINES, INC.|
|Date: September 5, 2023||By:|
|Mark A. Goldsmith, M.D., Ph.D.|
|President and Chief Executive Officer|